for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oragenics Inc

OGEN.K

Latest Trade

0.46USD

Change

-0.01(-1.09%)

Volume

129,521

Today's Range

0.46

 - 

0.47

52 Week Range

0.35

 - 

1.67

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.47
Open
0.46
Volume
129,521
3M AVG Volume
17.85
Today's High
0.47
Today's Low
0.46
52 Week High
1.67
52 Week Low
0.35
Shares Out (MIL)
46.12
Market Cap (MIL)
21.61
Forward P/E
-1.19
Dividend (Yield %)
--

Latest Developments

More

Oragenics Inc Resumes Phase 2 Clinical Trial Of Ag013 In Oral Mucositis Following Positive Routine Safety Review

EKF Diagnostics Signs Agreement With Oragenics

Empery Asset Management Lp Reports 9.99 pct Passive Stake In Oragenics Inc As Of July 13

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oragenics Inc

Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models.

Industry

Biotechnology & Drugs

Contact Info

4902 Eisenhower Blvd Ste 125

+1.813.2867900

https://www.oragenics.com/

Executive Leadership

Frederick W. Telling

Independent Chairman of the Board

Alan F. Joslyn

President, Chief Executive Officer, Director

Michael O'Keefe Sullivan

Chief Financial Officer, Treasurer, Secretary

Alan William Dunton

Independent Director

Robert C Koski

Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-0.870

2019(E)

-0.393
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.21
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.05
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-95.13
Return on Equity (TTM)
-84.91

Latest News

Latest News

BRIEF-Oragenics, Texas A&M University System Granted U.S. Patent For Lantibiotic MU1140

* ORAGENICS, INC. AND TEXAS A&M UNIVERSITY SYSTEM GRANTED U.S. PATENT FOR LANTIBIOTIC MU1140

BRIEF-Oragenics Announces Pricing Of $1.8 Million Registered Direct Offering

* ORAGENICS, INC. ANNOUNCES PRICING OF $1.8 MILLION REGISTERED DIRECT OFFERING

BRIEF-Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

* Oragenics doses first patient in phase 2 clinical trial of AG013 for oral mucositis

BRIEF-Oragenics announces completion of second closing of $3.0 million preferred stock private placement

* Oragenics announces completion of second closing of $3.0 million preferred stock private placement Source text for Eikon: Further company coverage:

BRIEF-Oragenics announces $3 mln preferred stock private placement and $2.4 mln loan

* Oragenics announces $3.0 million preferred stock private placement and $2.4 million loan

BRIEF-Oragenics receives audit opinion with going concern explanation

* Oragenics, Inc. receives audit opinion with going concern explanation Source text for Eikon: Further company coverage:

BRIEF-Oragenics board authorized to increase authorized shares of stock from 100 mln shares to 250 mln shares

* Oragenics - board authorized to increase authorized shares of stock from 100 million shares to 250 million shares - sec filing Source text (http://bit.ly/2jNqM0P) Further company coverage:

BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis

* U.S. FDA grants fast track designation for the development of Oragenics' AG013 for oral mucositis

BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017

* Oragenics - expects to file an investigational new drug (ind) update and initiate a phase 2 study with ag013 in united states and europe in early 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up